Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives: To investigate if the nicotine metabolite ratio (NMR, the ratio of nicotine metabolites 3'-hydroxycotinine/cotinine) is a reliable phenotypic biomarker for nicotine clearance across races, and as a function of differences in the rate of nicotine, cotinine and 3'-hydroxycotinine glucuronidation and UGT genotypes.
Methods: Participants [Caucasians (Whites), African Americans (Blacks) and Asian-Americans (Asians)] received an oral solution of deuterium-labeled nicotine and its metabolite cotinine. Plasma and saliva concentrations of nicotine and cotinine were used to determine oral clearances. Rates of glucuronidation were assessed from urine glucuronide/parent ratios, and UGT2B10 and UGT2B17 genotypes from DNA.
Results: Among the 227 participants, 96 (42%) were White, 67 (30%) Asian and 64 (28%) Black. Compared to the other two races, Whites had higher nicotine and cotinine total oral clearance, Blacks had lower nicotine and cotinine glucuronidation rates and Asians had lower 3'-hydroxycotinine glucuronidation rates. A strong positive correlation (correlations coefficients 0.77-0.84; P < 0.001) between NMR and nicotine oral clearance was found for all three races, and NMR remained a strong predictor for the nicotine oral clearance while adjusting for race, sex and age. Neither the metabolite glucuronidation ratios nor the UGT genotypes had significant effects on the ability of NMR to predict nicotine oral clearance.
Conclusion: NMR appears to be a reliable phenotypic biomarker for nicotine clearance across races, glucuronidation phenotypes and genotypes. Racial differences in the relationships between NMR, smoking behaviors and addiction are unlikely to be related to an inadequate estimation of nicotine clearance on the basis of NMR.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184575 | PMC |
| http://dx.doi.org/10.1097/FPC.0000000000000427 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biomarkers of Exposure to Tobacco-Related Toxicants among Adult Nicotine Pouch Users.
Nicotine Tob Res
September 2025
College of Public Health, University of Nebraska Medical Center, Omaha, NE, United States.
Introduction: Nicotine pouches (NPs) are an emerging nicotine delivery system. Understanding nicotine and toxicant exposure among NP users compared with users of other tobacco products and non-users is critical for informing public health strategies.
Methods: Data (n = 4527) were drawn from the Population Assessment of Tobacco and Health Study Wave 7 (2022-2023).
Efficacy and Safety of NFL-101 as a Smoking Cessation Therapy: A Randomized Phase II Clinical Trial CESTO2.
Nicotine Tob Res
August 2025
NFL Biosciences, Castelnau-Le-Lez, France.
Introduction: Tobacco addiction remains a major public health challenge. Existing smoking cessation treatments require prolonged daily use with potentially poor adherence and reduced efficacy.
Methods: The phase II study was a multicenter, randomized, double-blind, placebo-controlled trial with a one-year follow-up to assess the efficacy, safety, and immunogenicity of NFL-101 as a potential aid for smoking cessation.
Electronic cigarette use and risk of chronic kidney disease: a dose-response analysis with propensity score matching in a nationally representative cohort.
BMC Public Health
August 2025
Department of Urology, Kaifeng155 Hospital, RongTong Medical Healthcare Group Co.Ltd, Kaifeng, 475000, China.
Background: The long-term renal effects of electronic cigarette (e-cigarette) use remain poorly understood, despite its global rise as a nicotine delivery system. This study investigates the association between e-cigarette use and chronic kidney disease (CKD), with emphasis on dose-response relationships, subgroup heterogeneity, and adjustment for cigarette smoking.
Methods: We analyzed data from 872 adults in NHANES (2017-2020).
Use of nicotine replacement therapy to create a smoke-free home: study protocol for a pilot randomised controlled trial of a smoke-free home intervention in Scotland.
BMJ Open
August 2025
Institute for Social Marketing and Health, Faculty of Health Sciences and Sport, University of Stirling, Stirling, Scotland, UK.
Introduction: The harmful health effects of children's exposure to secondhand smoke (SHS) are well established. Most SHS exposure now occurs in the home, in low-income households. Previous research suggests that using nicotine replacement therapy (NRT) in the home can help with temporary smoking abstinence and could reduce smoking indoors.
View Article and Find Full Text PDFUrinary tobacco and nicotine exposure biomarkers as predictors of transitions between cigarette and e-cigarette use in the Exhale longitudinal cohort study.
Nicotine Tob Res
August 2025
Department of Medicine, University of Wisconsin, Madison, WI.
Introduction: Urinary tobacco and nicotine exposure biomarkers may be predictive of subsequent transitions in product use.
Methods: We used data from an observational study of 371 adults who smoked cigarettes daily, some of whom also used e-cigarettes, and who were followed every two months for up to two years (Wisconsin, US, 2015-19). Using a multistate transition model, we assessed continuous associations between transition propensities and urinary tobacco biomarker concentrations, namely 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol) (NNAL) and NE-2 (cotinine + trans-3'-hydroxycotinine), the nicotine metabolite ratio (NMR; trans-3'-hydroxycotinine:cotinine), and NNAL:NE-2, measured every 4 months.